Overnight strategic placement raises A$1.2 million to advance first-in-class PD1 armored MSLN CAR-T Therapy

• AdAlta has received firm commitments to raise A$1.2 million from a restricted group of high-net-worth investors at A$0.005 per Share.

• For every two Subscription Shares issued, the Company will issue one Attaching Option exercisable at A$0.01, with an expiry date of 3 June 2028 (ASX:1ADO).

• Strong demand from new and existing sophisticated and professional investors following AdAlta’s groundbreaking cancer therapy collaboration with Shanghai Cell Therapy Group.

• Placement facilitated by Lead Manager, 62 Capital Pty Ltd.

• Proceeds provide balance sheet flexibility, strengthening AdAlta’s position as it advances its “East to West” cellular immunotherapy strategy